- Home
- SBFG vs AARD Comparison
SBFG vs AARD Comparison
Compare SBFG & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | AARD |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 165.8M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SBFG | AARD |
|---|---|---|
| Price | $27.55 | $6.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 11.4K | ★ 120.3K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 27.33 | ★ 43.11 |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.16 | $3.35 |
| 52 Week High | $28.38 | $17.94 |
Technical Indicators
Market Signals| Indicator | SBFG | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 53.15 |
| Support Level | $20.94 | $5.12 |
| Resistance Level | $28.38 | $8.02 |
| Average True Range (ATR) | 0.79 | 0.88 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 65.76 | 59.50 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.